Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 143-150 , April 2011

Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

Received 16 April 2010 ,Revised 25 May 2010 ,Accepted 26 May 2010.

References 

  1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544
  2. Postmus PE, Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol. 2001;28:48–52
  3. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–1270
  4. Ebi N, Kubota K, Nishiwaki Y, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol. 1997;27:166–169
  5. Rosti G, Bevilacqua G, Bidoli P, et al. Small cell lung cancer. Ann Oncol. 2006;17(Suppl. 2):ii5–ii10
  6. Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23:1697–1699
  7. Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–1411
  8. Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol. 2003;30:72–78
  9. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist. 2004;9(Suppl 6):4–13
  10. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301. J Clin Oncol. 2006;24:5448–5453
  11. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol. 2008;26:5401–5406
  12. Evans WK, Feld R, Osoba D, et al. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer. 1984;53:1461–1466
  13. Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern cancer study group trial. Cancer Treat Rep. 1986;70:583–587
  14. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91
  15. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043
  16. Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–2535
  17. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229
  18. Pallis AG, Agelidou A, Agelaki S, et al. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung cancer. 2009;65:187–191
  19. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res. 1997;88:1205–1210
  20. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern cooperative oncology group study. J Clin Oncol. 1995;13:1430–1435
  21. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–351
  22. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung cancer. 2003;42:97–102
  23. Chan DC, Chen VJ, Zhang Z, et al. Studies of pemetrexed, gemcitabine, alone, in combinations, in human lung cancer models. ASCO Meeting Abs. 2006;24:17114
  24. Jalal S, Ansari R, Govindan R, et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier oncology group phase II study. J Thorac Oncol. 2009;4:93–96
  25. Gronberg BH, Bremnes RM, Aasebo U, et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung cancer. 2009;63:88–93
  26. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27:4787–4792
  27. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009;27:2046–2051
  28. Planting AS, Splinter TA, Ardizzoni A, et al. Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC lung cancer cooperative group. Cancer Chemother Pharmacol. 1992;29:409–411
  29. Ardizzoni A, Antonelli G, Ricci S, et al. Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. Am J Clin Oncol. 2000;23:22–25
  30. Sessa C, Wanders J, Roelvink M, et al. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC early clinical studies group (ECSG). Ann Oncol. 2000;11:207–210
  31. Samantas E, Kalofonos H, Linardou H, et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic cooperative oncology group study. Ann Oncol. 2000;11:1395–1397
  32. Schmittel A, Knodler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung cancer. 2007;55:109–113
  33. Eisen T, Thatcher N, Leyvraz S, et al. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung cancer. 2009;64:60–65
  34. Evans WK, Osoba D, Feld R, et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol. 1985;3:65–71
  35. Figoli F, Veronesi A, Ardizzoni A, et al. Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. Cancer Invest. 1988;6:1–5
  36. Masuda N, Fukuoka M, Matsui K, et al. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer. 1990;65:2635–2640
  37. Batist G, Carney DN, Cowan KH, et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986;4:982–986
  38. Porter LL, Johnson DH, Hainsworth JD, et al. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep. 1985;69:479–481
  39. Sculier JP, Lafitte JJ, Lecomte J, et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol. 2002;13:1454–1459
  40. Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung cancer. 2004;44:121–127
  41. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung cancer. 2002;37:319–323
  42. Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung cancer. 2003;40:333–338
  43. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1998;16:3329–3334
  44. Schuette W, Nagel S, Juergens S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer. 2005;7:133–137
  45. Rocha-Lima CM, Herndon JE, Lee ME, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902. Ann Oncol. 2007;18:331–337
  46. Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer. 2004;91:659–665
  47. Kim Y, Goto K, Nishiwaki Y, et al. Phase II study of weekly cisplatin, etoposide, irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). ASCO Meeting Abs. 2006;24:7088
  48. Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 1999;17:927–932
  49. Kakolyris S, Mavroudis D, Tsavaris N, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 2001;12:193–197
  50. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern cancer study group. J Clin Oncol. 1992;10:282–291
  51. Postmus PE, Smit EF, Berendsen HH, Haaxma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Semin Oncol. 1992;19:17–23
  52. Postmus PE, Smit EF, Kirkpatrick A, Splinter TA. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC lung cancer cooperative group. Eur J Cancer. 1993;29A:204–207
  53. Falk SJ, Maughan TS, Laurence VM, et al. Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol). 1993;5:85–88
  54. Faylona EA, Loehrer PJ, Ansari R, et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier oncology group trial. J Clin Oncol. 1995;13:1209–1214
  55. Kubota K, Nishiwaki Y, Kakinuma R, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol. 1997;15:292–296
  56. Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy. 2002;49:200–205
  57. Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier oncology group trial. Am J Clin Oncol. 2000;23:68–70
  58. Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 2001;19:119–126
  59. Isobe K, Kobayashi K, Kosaihira S, et al. Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer. Lung cancer. 2009;66:350–354
  60. Dongiovanni V, Buffoni L, Berruti A, et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol. 2006;58:203–209
  61. Leighl NB, Goss GD, Lopez PG, et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung cancer. 2006;52:327–332
  62. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the lung cancer cooperative group. J Clin Oncol. 1997;15:2090–2096
  63. Eckardt J, Gralla R, Palmer MC, et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol. 1996;7(suppl 5):107
  64. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer. 1997;18(1):35
  65. Takeda K, Negoro S, Sawa T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer. 2003;4:224–228
  66. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996;14:2785–2790
  67. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  68. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19:1743–1749
  69. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092
  70. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447
  71. Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res. 1989;80:69–76
  72. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res. 1989;80:77–82
  73. Suzuki T, Minamide S, Iwasaki T, et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs. 1997;15:219–225
  74. Noda T, Watanabe T, Kohda A, et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 1998;16:121–128
  75. Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res. 1998;89:1067–1073
  76. Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y. Phase I-II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer. ASCO Meeting Abs. 1995;14:361
  77. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan thoracic oncology group (WJTOG) study. Invest New Drugs. 2007;25:253–258
  78. Okamoto I, Hamada A, Matsunaga Y, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol. 2006;57:282–288
  79. Igawa S, Yamamoto N, Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol. 2007;2:741–744
  80. Kato T, Nokihara H, Ohe Y, et al. PhaseII trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). ASCO Meeting Abstracts. 2006;24:7061
  81. Kaira K, Sunaga N, Tomizawa Y, et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 2010;69:99–104
  82. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2098–2603
  83. Jotte R, Conkling P, Reynolds C, et al. Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy. ASCO Meeting Abs. 2009;27:8028
  84. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9:5880–5887
  85. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005;16:1811–1816
  86. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer. 2005;103:2128–2131
  87. Burger H, den Bakker MA, Stoter G, et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer. 2003;39:793–799
  88. Lucchi M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg. 2002;21:1105–1110
  89. Jalal SI, Bhatia S, Einhorn LH, et al. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a safety, feasibility, efficacy trial from the Hoosier oncology group. ASCO Meeting Abs. 2008;26:19013
  90. Ramalingam SS, Mack PC, Vokes EE, et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California consortium phase II study (NCI # 7097). ASCO Meeting Abss. 2008;26:8078
  91. Gitlitz BJ, Glisson BS, Moon J, Reimers H, Gandara DR. Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial. ASCO Meeting Abs. 2008;26:8039
  92. Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier oncology group phase II trial. Lung Cancer. 2006;52:93–97
  93. Langer SW, Pedersen BS, Ranson M, Pappot H, Loft A, Thatcher N. Phase II study of iressa (GEFITINIB) in relapsed and refractory small cell lung cancer (SCLC). J Thorac Oncol. 2008;3:S55
  94. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol. 2009;39:137–150
  95. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol. 2004;15:1187–1193

PII: S0305-7372(10)00103-9

doi: 10.1016/j.ctrv.2010.05.004

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 143-150 , April 2011

Article Tools